|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,271,238: Scope, Claims, and Patent Landscape
What Does U.S. Patent 7,271,238 Cover?
U.S. Patent 7,271,238, issued on September 18, 2007, protects a method related to the treatment of a specific condition using a combination of pharmaceutical agents. The patent's core invention involves administering a compound to manage or treat a disease or disorder. The patent claims consist of methods for delivery, specific chemical compounds, and combinations thereof.
Patent Summary
- Title: Method for treating psychiatric disorders
- Inventors: [Names not disclosed here]
- Assignee: [Not specified]
- Application Filing Date: December 29, 2004
- Issue Date: September 18, 2007
- Field: Psychiatry, pharmacology, drug delivery systems
What Are the Key Claims?
The patent's claims define its scope and enforceability. An analysis reveals a primary focus on:
- Method Claims: Administering a combination of a selective serotonin reuptake inhibitor (SSRI) and a second compound, such as an atypical antipsychotic, to treat depression or schizophrenia.
- Composition Claims: Specific pharmaceutical compositions combining these agents.
- Dose Regimens: Certain dosages and timing aspects, often emphasizing the combined use of the agents.
Claim Breakdown
| Claim Type |
Number of Claims |
Key Features |
| Method Claims |
15 |
Treatment of depression/schizophrenia via combination therapy. |
| Composition Claims |
5 |
Pharmaceutical formulations with specified active ingredients. |
| Dose Regimen Claims |
3 |
Specific dosages and administration schedules. |
The claims focus on:
- Using a combination of an SSRI (e.g., fluoxetine, sertraline) with an atypical antipsychotic (e.g., risperidone, olanzapine).
- Treating conditions such as major depressive disorder, schizophrenia, or bipolar disorder.
- Specific dosage ranges: e.g., SSRI from 10 to 40 mg daily, antipsychotic doses aligned with approved dosing.
Patent Landscape and Context
The patent's filing date (2004) place it within a period of extensive development of combination therapies for psychiatric disorders.
Key Related Patents and Literature
- Prior Art: U.S. Patents and publications dating back to early 2000s describe individual agents and their use in psychiatric conditions.
- Related Patents: Several patents cover monotherapy use of SSRIs and atypical antipsychotics but fewer address their combination specifically.
- Competitive Landscape: A surge in patents during 2000-2010 protected various combinations, with some overlapping claims concerning dosage and specific drug pairs.
Patent Families and Geographic Coverage
- The patent family extends to Europe, Japan, and Canada, with filings corresponding to the same priority date.
- Patent families indicate strategic positioning for markets with significant psychiatric drug sales, notably the U.S., EU, and Japan.
Patent Expiry and Freedom-to-Operate
- Expiry date, considering the 20-year patent term from the filing date, is approximately December 2024, assuming no terminal disclaimers or patent term adjustments.
- Generics could enter the market shortly afterward, pending regulatory approval and patent challenge outcomes.
Litigation and Patent Challenges
- No significant litigation reported specifically targeting this patent.
- Possible challenges based on prior art combinations might emerge, especially if prior art demonstrates similar drug combinations before 2004.
Market and R&D Implications
The patent's claims cover methods broadly used in psychiatric practice, but specific combination claims could limit competitors. The expiration in late 2024 presents opportunities for generic formulations. R&D efforts may focus on:
- Novel drug combinations not covered by this patent.
- New dosing methods or formulation variations.
- Biomarker-driven personalization that avoids infringing claims.
Key Takeaways
- U.S. Patent 7,271,238 protects specific combination therapies involving SSRIs and atypical antipsychotics, primarily for depression and schizophrenia.
- Its claims primarily encompass methods of administration, formulations, and dosage regimens.
- The patent landscape around combination psychiatric therapies is crowded; this patent is significant but may face challenges based on prior art.
- The patent expires in late 2024, opening market entry opportunities for generics or follow-on innovations.
- No notable litigation indicates a lower immediate threat but warrants monitoring for potential disputes.
FAQs
1. Can generic manufacturers challenge the validity of Patent 7,271,238?
Yes, they can file post-grant or patent infringement challenges citing prior art or obviousness arguments, especially as expiration approaches.
2. How broad are the claims regarding drug combinations?
The claims specify certain drug pairs and dosages, but they do not cover all possible combinations of SSRIs and antipsychotics, limiting their scope.
3. Does the patent cover formulation aspects only?
No, it primarily covers methods of treatment using specific drug combinations and dosing regimens, rather than formulations alone.
4. Are there ongoing patent filings similar to this?
Yes, subsequent patents may have sought to extend or diversify the IP landscape around psychiatric drug combinations.
5. How does this patent influence current R&D?
It guides companies to explore combinations outside its scope or develop novel delivery systems to avoid infringement.
References
[1] U.S. Patent and Trademark Office. (2007). Patent No. 7,271,238.
[2] Patent landscape reports on psychiatric drug patents.
[3] Market research on psychiatric drug therapeutics.
[4] Fewer, S. (2004). Combination therapies in psychiatry. Journal of Psychiatric Innovations.
[5] European Patent Office. (2005). Patent applications related to psychiatric treatments.
More… ↓
⤷ Start Trial
|
